Comparison · NCT01950819-fa1c08a5
EVR+rCNI vs MPA+sCNI: Incidence of Malignancies.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. EVR+rCNI vs MPA+sCNI: Incidence of Malignancies. Trial comparisons, record NCT01950819-fa1c08a5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01950819-fa1c08a5
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0404 | 0.0299 | 0.0544 | wilson | |
| Risk in group 2 | 0.0385 | 0.0283 | 0.0522 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0019 | -0.0154 | 0.0192 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.05 | 0.683 | 1.61 | log | |
| Odds ratio, group 1 over group 2 | 1.05 | 0.672 | 1.64 | log | |
| Number needed to treat, for one more participant with the outcome on EVR+rCNI than on MPA+sCNI | 527 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | EVR+rCNI | Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus) | 41 | 1,014 | OG000 |
| Group 2 | MPA+sCNI | Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus). | 39 | 1,012 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Incidence of Malignancies.
- Description
- Incidence of malignancies.
- Time frame
- Month 24
- Population
- safety set
Source ClinicalTrials.gov
Trial
- Title
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
- NCT number
- NCT01950819
- Phases
- PHASE4
- Conditions
- End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy, Renal Transplantation
- Interventions
- Induction therapy, Corticosteroids, EVR+rCNI, MPA+sCNI
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2019-01-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01950819?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01950819-fa1c08a5